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Angiogenesis is a key factor in early stages of wound healing and is crucial for the repair of vascularized tissues such as the bone.
However, supporting timely revascularization of the defect site still presents a clinical challenge. Tissue engineering approaches
delivering endothelial cells or prevascularized constructs may overcome this problem. In the current study, we investigated
platelet-rich plasma (PRP) gels as autologous, injectable cell delivery systems for prevascularized constructs. PRP was produced
from human thrombocyte concentrates. GFP-expressing human umbilical vein endothelial cells (HUVECs) and human bone
marrow-derived mesenchymal stem cells (MSCs) were encapsulated in PRP gels in diﬀerent proportions. The formation of
cellular networks was assessed over 14 days by time-lapse microscopy, gene expression analysis, and immunohistology. PRP gels
presented a favorable environment for the formation of a three-dimensional (3D) cellular network. The formation of these
networks was apparent as early as 3 days after seeding. Networks increased in complexity and branching over time but were
only stable in HUVEC-MSC cocultures. The high cell viability together with the 3D capillary-like networks observed at early
time points suggests that PRP can be used as an autologous and proangiogenic cell delivery system for the repair of vascularized
tissues such as the bone.
1. Introduction
Angiogenesis is crucial for healing and regeneration of vascu-
larized tissues such as the bone [1]. In this process, new cap-
illaries sprout from preexisting vessels to support expanding
vascular networks. In the case of large musculoskeletal
defects, the surrounding tissue is usually damaged, which
may pose a problem since an adequate supply of oxygen
and nutrients at the injury site is essential for proper healing
[2]. To date, this constitutes still a clinical challenge, because
on the one hand, the distance which can be reached by angio-
genic sprouting is limited, and on the other hand, the
ingrowth of new vessels is a slow process with 5μm/h [3].
Replacement of the damaged tissue might be a suitable
option but is often constricted by the availability of trans-
plantable graft material, for example, bone grafts. Cell-
based tissue engineering strategies may overcome these
problems. However, it has been shown that the ingrowth of
vessels into grafts, as well as the repopulation with endothe-
lial cells into grafts, is not rapid enough to ensure a suﬃcient
blood supply of the grafted cells/tissue [4–6]. In contrast,
preformed networks could be linked to existing vessels within
2–4 days [6, 7]. These ﬁndings strongly suggest the use of
prevascularized constructs [8].
Cell-based prevascularization of tissue-engineered con-
structs, using endothelial cells [9–12], endothelial progenitor
cells (EPCs) [13–15], or microvascular fragments [16],
showed promising results, supporting a fast anastomosis to
the host vascular system. Interestingly, it has variously been
shown that mural cells, such as mesenchymal stem cells
(MSCs), or ﬁbroblasts further promote the vascularization
process [9, 10, 13, 15].
The culture and expansion of EPCs and endothelial
cells, for example, HUVECs, require proangiogenic growth
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factors. Such recombinant growth factors are expensive
and discussed controversially [17]. The supplementation
of growth medium with autologous growth factors would
be desirable for clinical application. Platelets are part of
the blood and contain more than 5000 proteins. About 300
of the contained proteins, especially growth factors and
cytokines, are released upon activation [18–20]. The release
of cytokines, chemokines, and growth factors induces pro-
liferation and activation of the cells that are involved in
wound healing such as ﬁbroblasts, neutrophils, monocytes,
smooth muscle cells, and MSC [21]. In addition, our pre-
vious work has demonstrated that platelet-derived growth
factors can be eﬃciently used as culture supplement for
EPCs [15, 22, 23].
In the last two decades, the treatment with platelet-
related plasma (PRP), deﬁned as suspended plasma which
contains at least 200,000–1,000,000 platelets/μl suspended
plasma [24], is upcoming. PRP can be produced by commer-
cial centrifuges and is used for various clinical applications in
the ﬁeld of orthopedics, for example, cartilage repair [25, 26],
ligament healing [27–29], and tendon healing [30–32].
Although PRP provides a spectrum of growth factors
released by platelets, there is no common deﬁnition of PRP
preparations and often PRP products have not been system-
atically tested in clinical trials [33–35], both hindering
comparisons between diﬀerent studies.
Thrombin and/or calcium chloride are commonly used
to activate platelets in PRP [36], which provokes the release
of biomolecules and cleavage of ﬁbrinogen resulting in the
formation of a ﬁbrin gel. Therefore, activated PRP can be
used as an autologous hydrogel [37–39]. Taking advantage
of an autologous system, PRP has been applied for various
in vitro and in vivo studies. Due to its high content of growth
factors, such as platelet-derived growth factor (PDGF), trans-
forming growth factor β (TGF-β), and insulin-like growth
factor (IGF) [40], PRP has been used for various applications
of musculoskeletal regeneration, orthopedics, and the treat-
ment of ischemic diseases [13, 41–44]. We have recently
demonstrated that PRP gels can be used as a cell delivery sys-
tem for MSCs [33]. In this study, we showed that PRP sus-
tained viability and promoted proliferation of encapsulated
MSCs in a platelet concentration-dependent manner.
Based on promising preliminary data [45], the aim of the
present study was to investigate the angiogenic properties of
PRP gels and to evaluate whether PRP can be used as an
autologous delivery system for prevascularized structures
supporting early neovascularization.
2. Methods
2.1. Bone Marrow- (BM-) Derived Mononuclear Cell (MNC)
Isolation and Cell Culture. BM aspirates were obtained from
vertebra of patients undergoing orthopedic surgery after
informed consent and approval by the local ethics committee
(EK Regensburg 12-101-0127). Mononucleated cells (MNCs)
were isolated from BM aspirates (n = 4) by density centrifu-
gation with Ficoll (Histopaque®-1077, Sigma). MNCs were
seeded in tissue culture ﬂasks at a density of 5× 104 cells/
cm2 in αMEM (Gibco) containing 10% FBS (Seraplus, Pan)
and 5ng/ml bFGF (R&D Systems). After 4 days in culture,
nonadherent hematopoietic cells were removed. Mesenchy-
mal stem cells (MSCs) selected by adherence to cell culture
plastic were further expanded with a change of medium every
3 days. Cells were passaged when 80% conﬂuency was
reached, detached using 1% trypsin-EDTA and reseeded at
a density of 3× 103 cells/cm2. All MSCs were used from pas-
sages 2 to 4.
GFP-expressing HUVEC cells (HUVEC-GFP, Angio-
Proteomie) were cultured on coated plates (Speed Coating
Solution, PELObiotech) in complete EGM-2 growth
medium (Lonza) at a seeding density of 5× 103 cells/cm2
and subcultured upon 80% conﬂuency. Cells were used
in passages 7–9.
2.2. Cell Labeling of MSCs. For live cell imaging, MSCs were
labeled with PKH26® Red Fluorescent Cell Linker Kit for
General Cell Membrane Labeling (Sigma Aldrich) prior
encapsulation in PRP gels. After detaching and counting of
cells, the desired amount of cells were pipetted in a new fal-
con tube, washed with serum-free αMEM and centrifuged
at 400g for 5min. Cells were resuspended in Diluent C
(Sigma) and ﬁltered using a 40μm cell strainer, and dye
working solution was added (2μl PKH26 Red/1× 106 MSCs)
and incubated for 5min at room temperature. The labeling
reaction was stopped by addition of FBS (SeraPlus), and cells
were washed three times with medium and the cell count was
determined.
2.3. Preparation of PRP. PRP was produced from human
leukocyte-depleted thrombocyte concentrates (blood bank,
Kantonsspital Graubünden, Chur, Switzerland) obtained by
apheresis containing 1000× 103 platelets/μl and less than 2
leukocytes/μl. In order to reach an approximately 10-fold
increased platelet concentration compared to physiological
blood concentration (150–300× 103 platelets/μl), the platelet
concentrates were centrifuged at 2000g for 20min. The
resulting pellet was resuspended in half of the original vol-
ume of platelet-depleted plasma, resulting in PRP with
2000× 103 platelets/μl. PRP was homogenized by sonication
for 15min and stored at −20°C until use. PRP samples
(n = 3) were pooled and randomly matched to normalize
for any donor-speciﬁc inﬂuences.
2.4. Encapsulation of Cells in PRP Gels. For the incorporation
of cells into PRP gels, PRP aliquots (pool of 3 donors) were
thawed. Cells were seeded in PRP gels at a density of
2.5 × 103 cells per μl gel. For time-lapse microscopy, a gel vol-
ume of 20μl was seeded in μ-slides (μ-Slide Angiogenesis,
Ibidi); for histology and gene expression analysis, 120μl gels
were prepared in 96-well plates. Monocultures of each cell
type and cocultures were performed as follows: 100% MSCs
(100M), 100% HUVECs (100H), 75% HUVECs–25% MSCs
(75HM), and 50% HUVECs–50% MSCs (50HM). Cells
were resuspended in PRP and gelation induced by addition
of human thrombin (Tisseel, Baxter, ﬁnal concentration
5U/ml) and incubation at 37°C for 15–30min. All gels were
cultured under static conditions at 37°C and 5% CO2 in
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EGM-2 growth medium (Lonza) with 5 μM ε-aminocaproic
acid (Sigma).
2.5. Microscopy and Image Analysis. The μ-slides with PRP
gels were placed in an onstage incubator linked to an EVOS™
FL Auto Cell Imaging System (ThermoFisher Scientiﬁc). The
cellular network formation capacity of HUVECs and MSCs
in diﬀerent proportions was analyzed using time-lapse
microscopy. Regions of interest were deﬁned before starting
of the time lapse to allow tracking of individual cells. Pictures
were taken every three hours for 14 days and medium chan-
ged every two days. At the end of the experiment, gels were
imaged using a LSM 510 confocal imaging system, equipped
with an argon and a HeNe1 laser, and mounted on an Axio-
vert200m microscope with ZEN black software (all Zeiss).
Gels were imaged using the 10x and 20x objective at
1272×1272 and 2028×2028 pixel, respectively.
Image analysis of cellular networks was performed as
described before [46]. In brief, the PKH26 Red-labeled MSCs
(Figure 1(a)) were imaged with the RFP ﬁlter and GFP-
HUVECs (Figure 1(b)) with the GFP ﬁlter (both Thermo-
Fisher Scientiﬁc). The combined images of both ﬂuores-
cences (Figure 1(c)) generated with the EVOS FL Auto Cell
Imaging System (ThermoFisher Scientiﬁc) were imported
in Axiovision Software (version 4.9.1, Zeiss). For quantiﬁca-
tion of cellular networks, any tubular structures were marked
with a polygon area (Figure 1(d)) and the area measured. The
image analysis was performed with the KS400 software
(Zeiss) and a custom-made macro. An individual threshold
was set for the images of the red-labeled MSCs and GFP-
HUVECs, and the area of the respective ﬂuorescent dye
within the region of interest was calculated.
2.6. Gene Analysis. Two sample gels were taken and pooled at
diﬀerent time points for gene expression analysis: day 0 (d0),
day 7 (d7), and day 14 (d14). For RNA extraction, pooled gels
were lysed in 1ml TriReagent (Sigma) and supplemented
with 5μl Polyacryl Carrier (Molecular Research Center)
using a TissueLyser (Qiagen) at 25Hz for 7min. After centri-
fugation at 12000g for 10min at 4°C, 10% bromochloropro-
pane was added and samples were centrifuged at 12000g for
15min at 4°C for phase separation. The upper, aqueous phase
was collected, and RNA was precipitated using cooled 70%
ethanol. RNeasy columns (Qiagen) were used for RNA
puriﬁcation according to the manufacturer’s instructions.
RNA purity and concentration was measured with the
NanoDrop system (Witec GmbH). Samples were stored at
−80°C until use.
cDNA was synthesized from 600ng RNA using Taq-
Man® Reverse Transcription reagents (Applied Biosystems,
Invitrogen) with random hexamer primers. Real-time PCR
was performed using 6ng cDNA and TaqMan Master Mix
(Applied Biosystems) using a Quant Studio 6 Flex machine
(Applied Biosystems). Genes of interest were detected
using TaqMan Gene Expression Assays (Applied Biosys-
tems) for angiopoietin 1 (Hs00181613_m1), CD146/MCAM
(a) (b)
(c) (d)
Figure 1: Network analysis. Image analysis method of PRP gels (seeding density: 2.5× 103 cells/μl gel) with encapsulated PKH26 Red-labeled
MSCs and GFP-HUVECs (green). Shown are representative pictures of a 50% HUVEC–50% MSC coculture after 14 days of culture.
(a) Red-labeled MSCs, (b) GFP-labeled HUVECs, and (c) combined image. (d) Tubular structures are marked with the polygons (grey).
Scale bar = 200μm.
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(Hs00174838), NG-2/CSPG 4 (Hs00426981_m1), con-
nexin 43 (Hs00748445_s1), collagen IV (Hs00266237_m1),
platelet-derived growth factor receptor β1 (PDGFRβ1)
(Hs00182163_m1), and Tie 2/Tek receptor (Hs00176096).
Vascular endothelial growth factor A (VEGF A) was detected
using forward primer 5′-GCC CAC TGA GGA GTC CAA
CA-3′, reverse primer 5′-TCCTATGTG CTG GCC TTG
GT-3′, and probe 5′-CAC CAT GCA GAT TAT GCG GAT
CAA ACC T-3′ (Microsynth). As an endogenous control,
human 18s (Hs99999901_m1, ThermoFisher Scientiﬁc)
was used. All samples were measured in duplicates, and
data are presented relative to day 0 using the comparative
ΔΔCT method.
2.7. Histology. Histological analysis was performed of gels
with mono- and cocultures after 14 days of incubation. Gels
were washed once with PBS and then placed in cryomolds
with cryocompound Tissue Freezing Medium (Jung). After
15min of incubation, samples were snap frozen in isopentane
and stored at −20°C until use.
Snap-frozen samples were cut in 20μm thick slices. For
immunohistology, cuts were ﬁxed in 70% methanol for
15min, rehydrated in dH2O, and incubated for 30min in
99.5% methanol with 30% H2O2 to block endogenous perox-
idase activity. After blocking for unspeciﬁc antibody binding
with horse serum (dilution 1 : 20) at room temperature for
60min, the primary antibodies connexin 43 (ThermoFisher
Scientiﬁc) and CD146 (abcam) were put onto the slides (ﬁnal
concentration: 5μg/μl connexin 43; 1μg/μl CD146) and incu-
bated for 30min. Controls were incubated with PBS contain-
ing 0.1% Tween (PBST). Afterwards, slides were washed
three times with PBST and incubated for 60min with a
secondary anti-mouse antibody (Vectastain ABC kit) at a
dilution of 1 : 200. Another washing step (3×PBST) was per-
formed, the ABC complex of the Vectastain ABC Elite kit was
applied, and slides were incubated for 30min. After washing
3×with PBST, slides were incubated with ImmunPACT
DAB in the dark for 4min, and after several water changes
in dH2O, slides were covered with Prolong Gold antifade
reagent with DAPI (ThermoFisher Scientiﬁc). Slides were
stored at room temperature until observation, and pictures
were taken using an Axioplan2 microscope equipped with
an AxioCamHRc camera and AxioVision software (Zeiss).
2.8. Statistics. All values are shown as mean± standard error
of the mean (SEM). Statistical analysis of data was performed
with GraphPad Prism 7 software. Normal distribution of
data was proven using the Shapiro-Wilk normality test.
Statistical diﬀerences between experimental groups were
tested by 2-way ANOVA and Tukey’s post hoc test for
multiple comparisons.
3. Results
3.1. Shrinkage of PRP Gels with Encapsulated MSCs. Figure 2
shows representative pictures of PRP gels with and without
cells taken at diﬀerent time points during the culture period.
PRP gels without cells retained their original shape, while
shrinkage occurred in cell-containing gels. After one week,
most pronounced shrinkage could be observed in gels with
MSCs monocultures, where gels shrinked to nearly half of
their original volume. Moreover, gels containing MSC-
HUVEC cocultures (50HM) demonstrated a reduced size,
whereas HUVEC-containing gels were not aﬀected. After
two weeks, the shrinkage was still ongoing, however, at a
slower rate. Again, shrinkage was most pronounced in gels
containing the highest concentrations of MSCs, suggesting
that this eﬀect was dependent on the number of encapsu-
lated MSCs.
3.2. Stable Cellular Networks Are Present in HUVEC-MSC
Cocultures after 14 Days. Cellular organization within PRP
gels was observed by time-lapse microscopy (Figure 3). In
HUVEC monocultures, the formation of networks was pres-
ent as early as 3 days after seeding. Branching and complexity
of the networks increased until day 10. Afterwards, structures
Without
cells
With cells
100 M 100 H 75 HM 50 HM
d0
d7
d14
Figure 2: MSCmediated shrinkage of PRP gels. PRP gels (120μl) were seeded either with or without cells in a 96-well plate. Diﬀerent types of
cells were encapsulated (seeding density: 2.5× 103 cells/μl gel): 100% MSCs (100M), 100% HUVECs (100 H), 75% HUVECs–25% MSCs
(75HM), 50% HUVECs–50% MSCs (50HM). Shown are representative pictures from day 0 (d0), day 7 (d7), and day 14 (d14). White
dashed lines indicate the outline of gels. Shrinkage was only observed when MSCs were present in gels.
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became disorganized. In contrast to HUVEC monocultures,
no networks could be detected in MSC monocultures. In
both cocultures (75HM and 50HM), cellular networks were
observed (Figure 3). Cells were well organized in networks
already after 3 days. Deﬁned networks could be observed
after one week of culture. In contrast to the monocultures,
these networks seemed to be stable for 2 weeks. To note,
the 3D nature of cellular networks often hindered a high-
quality imaging. To address this issue, high-resolution
images were taken with a confocal microscope at the end of
the study after 14 days (Figure 4). The ﬁndings were in line
with the observations from time-lapse imaging (Figure 3).
d0
d3
d7
100 H
d10
d14
75 HM 50 HM100 M 
Figure 3: Time-lapse pictures of HUVEC andMSCmono- and cocultures. GFP-positive HUVECs (green) and PKH26 Red prestained MSCs
were encapsulated in PRP (seeding density: 2.5× 103 cells/μl gel) and time-lapse microscopy ran for two weeks. Four diﬀerent cell proportions
were seeded: 100%MSCs (100M, ﬁrst column), 100% HUVECs (100H, second column), 75% HUVECs–25%MSCs (75 HM, third column),
and 50% HUVECs–50% MSCs (50 HM, fourth column). Representative pictures of ﬁve time points are shown: day 0 (d0), day 3 (d3), day 7
(d7), day 10 (d10), and day 14 (d14). Cellular organization towards formation of tube-like networks starting from day 3 was observed in
mono- and cocultures in PRP over time but not in the condition of 100% MSCs. After one week, a complex cellular network could be
detected in both cocultures which was still apparent after two weeks. Cellular networks in HUVEC monocultures disintegrated after 10
days. Scale bar = 200 μm.
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However, high magniﬁcation images revealed the contribu-
tion of MSCs to the networks (Figures 4(e) and 4(f)).
Based on time-lapse pictures, image analysis was
performed to investigate further the formation of cellular
networks in diﬀerent culture conditions (Figure 5). First, we
measured the relative percentage of green and red ﬂuores-
cence in the entire image, representing encapsulated
HUVECs and MSCs, respectively (Figures 5(a) and 5(b)). A
slight trend of increase in measured green ﬂuorescent signal
in the entire image was detected in all conditions by day 3
100 M 
(a)
100 H
(b)
75 HM 
(c)
50 HM
(d)
50 HM
(e)
50 HM
(f)
Figure 4: High-resolution images of HUVEC and MSC mono- and cocultures after 2 weeks. Representative images are shown from mono-
and cocultures at day 14 after seeding (seeding density: 2.5× 103 cells/μl gel) with (a) 100% MSCs (100M); (b) 100% HUVECs (100 H); (c)
75% HUVECs–25% MSCs (75 HM); and (d–f) 50% HUVECs–50% MSCs (50 HM). Network formation occurred in 100H and both
cocultures but was only stable in the presence of MSCs which integrate in cellular networks as demonstrated in e and f (white arrow
heads). Scale bar = 100μm (a–d), 25μm (e, f).
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(Figure 5(a)), raising from 28.7± 6.9% to 46.9± 16.4%,
from 28.4± 5.2% to 43± 3.3%, and from 27.3± 7% to
40.9% in 100H, 75HM, and 50HM cultures, respectively
(all p > 0 05). From there on, signals remained at a constant
level, or even decreased to baseline levels with 25± 6%,
42± 7.9%, and 29± 3.5% at day 14 for 100H, 75HM, and
50HM cultures, respectively. A similar pattern was
observed for the red ﬂuorescence signal, that is, the MSCs
(Figure 5(b)). These ﬁndings demonstrate that over the
course of the experiment, cells were apparent at least in a
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Figure 5: Analysis of cellular networks. Image analysis was performed of mono- and cocultures (100% HUVECs (100H), 75%
HUVECs–25% MSCs (75HM), and 50% HUVECs–50% MSCs (50HM)) in PRP (seeding density: 2.5× 103 cells/μl gel) (n = 3).
Networks were measured by manually marking cellular networks. The relative percentage of prestained green (HUVECs) and red
(MSCs) cells was investigated for day 0, day 3, day 7, day 10, and day 14 in the following regions: relative percentage of green or
red signal in the entire image (a, b), relative percentage of marked network area (c), relative percentage of green or red signal in
marked network area (d, e), and the relative percentage of green or red signal beside marked network area (f, g). For 100 H
monocultures, networks decreased after one week whereas in both cocultures, networks were present and stable after two weeks (c).
Cellular networks were mainly made out of HUVECs (d), with a minor contribution of MSCs (e). Two-way ANOVA with Tukey’s post
hoc test for multiple comparison was applied to test for signiﬁcant diﬀerences over time (compared to day 0: (A) 50HM p < 0 01 (all time
points); (B) 75HM p < 0 01 (day 3) and p < 0 001 (day 7–14); and (C) 100H p < 0 001 (day 3) and p < 0 01 (day 7)) and between diﬀerent
culture conditions (∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001 compared to 50HM, ###p < 0 001 compared to 75HM). n = 3.
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Figure 6: Gene expression of HUVEC and MSC mono- and cocultures in PRP at days 7 and 14. Gene expression (normalized to 18s
expression) at day 7 and day 14 is displayed as fold change to day 0. Dashed lines indicate a fold change of 1, that is, unchanged gene
expression. MSC monocultures (100M), HUVEC monocultures (100 H), and cocultures 75% HUVECs–25% MSCs (75 HM) and 50%
HUVECs–50% MSCs (50 HM) were investigated (seeding density: 2.5× 103 cells/μl gel). (a) Gene expression of VEGF, showing
downregulation in 100H cultures. (b) An upregulation of angiopoetin-1 (Ang 1), a crucial growth factor of angiogenic processes, was
detected in all conditions at day 14 as well as in the cocultures on day 7. (c) Gene expression of Tie 2, one of the receptors binding Ang 1.
(d–f) Depicted is the expression of pericyte markers CD146, NG 2, and PDGFRβ1, respectively. CD146 was upregulated at day 7 in MSC
monocultures (d). At day 7, both cocultures showed a higher NG 2 expression compared to monocultures (e). PDGFRβ1 upregulations
were detectable in all cultures at day 14 (f). MSCs upregulated connexin 43 (g), indicating the formation of gap junctions, whereas no
diﬀerential regulation was observed for collagen IV (h). Two-way ANOVA with Tukey’s post hoc test for multiple comparison was
applied to test for diﬀerences between experimental groups; ∗p < 0 05. n = 3.
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similar concentration as at day 0, suggesting that PRP oﬀers
an appropriate environment for cells over a time of 2 weeks.
Next, we analyzed the eﬃciency of network formation in
the diﬀerent culture conditions (Figure 5(c)). Results showed
that the main parts of networks were built within the ﬁrst
three days in all conditions, with networks covering 56.3
± 21.3%, 42.4 ± 10.6%, and 45± 7% of the entire image area
in 100H, 75HM, and 50HM cultures, respectively (all
p < 0 01 compared to day 0). For 75HM and 50HM cocul-
tures, a stable high area of cellular networks which remained
constant over time (p < 0 01 compared to day 0 for all time
points) was observed with only minimal diﬀerences between
both culture conditions. While the speed of initial network
formation as well as the percentage of formed networks in
HUVEC cultures were comparable to cocultures until day 7
(p < 0 01 compared to day 0 for day 3 and day 7), networks
signiﬁcantly decreased after 10 days, revealing similar con-
centrations as on day 0 (p > 0 05). After 14 days, networks
were only observed in the cocultures with MSCs (53.5
± 8.3% for 75HM and 41.7± 5% for 50HM, versus 9.8 ± 1%
for 100H), which led to the suggestion that MSCs play a
fundamental role in the stabilization processes of newly
formed structures.
Finally, we investigated the contribution of HUVECs
(Figure 5(d)) or MSCs (Figure 5(e)) to the marked network
area. Analysis revealed that most HUVECs were involved
in the formation of networks in all conditions with a relative
contribution to the networks ranging from 55% to 87%
depending on the culture condition and time point. The
fast increase of the green signal measured in networks
(Figure 5(d)) aﬃrms again the speed of network formation
in all conditions. Although cellular networks were less stable
in 100H monocultures, the contribution of HUVECs to the
networks in these cultures was higher compared to cocultures
reaching statistical signiﬁcance from day 7 on (day 7: 100H
80.9± 0.2% versus 50HM 64.2± 4.8% (p < 0 05); day 10:
100H 75.7± 4.6% versus 50HM 55.2± 4.6% (p < 0 01);
and day 14: 100H 87± 0.9% versus 75HM 63.4± 3.8%
(p < 0 001) versus 50 HM 62.8± 3.3% (p < 0 001)). With
21–34% of the network area covered by red ﬂuorescence
signal, MSCs contributed to the networks as well, however,
to a lesser extent as HUVECs.
The ﬂuorescence signal detected outside the marked
network area (Figures 5(f) and 5(g)) reﬂects the timely
recruitment of cells to the networks at a merely constant
total cell number.
3.3. Analysis of Angiogenic Gene Expression in PRP
Gels Containing Cellular Networks.All PRP gels were analyzed
for the gene expression related to angiogenesis and vasculariza-
tion at day 7 and day 14 (Figure 6). First, we measured the
expression of VEGF (Figure 6(a)). Although VEGF plays an
important role in terms of new vessel formation, data shows
no upregulation of VEGF gene expression in PRP gels. How-
ever, in contrast to HUVEC monocultures, where VEGF
expression was downregulated, gene expression remained sta-
ble in cocultures (100H versus 75HM p < 0 05 at day 14)
and MSC monocultures. Of note, the lack of upregulation
of VEGF might be related to the fact that both the feeding
medium EGM-2 and PRP itself contain high levels of VEGF.
Another main growth factor involved in angiogenic
processes is angiopoietin 1, which showed a trend of
upregulation in all conditions (ranging from a fold change
of 4 to 7 in the diﬀerent culture conditions, p > 0 05) at
day 14 (Figure 6(b)). In line with the eﬃcient formation
of cellular networks in cocultures, angiopoietin 1 was spe-
ciﬁcally upregulated in these cultures at day 7 (75HM fold
change: 4.6± 1.7; 50HM fold change 8.4± 4) which was
however not statistically signiﬁcant (p > 0 05). In contrast
to these ﬁndings, the angiopoietin receptor Tie 2 did not
show a similar pattern as angiopoietin 1 (Figure 6(c)).
While Tie 2 gene expression was unchanged in most
culture conditions, a slight downregulation was detected
in cocultures at day 14 (p > 0 05).
100 M 100 H 75 HM 50 HM
NC
CD146
Cx 43
Figure 7: Immunohistology for CD146 and connexin 43 (Cx 43) of HUVEC and MSC mono- and cocultures in PRP at day 14.
Immunohistology was performed on cryosections of mono- and cocultures with 100% MSCs (100M), 100% HUVECs (100H), 75%
HUVECs–25% MSCs (75 HM), and 50% HUVECs–50% MSCs (50HM) (seeding density: 2.5× 103 cells/μl gel). Negative controls (NC)
are shown in the ﬁrst row. In comparison to the NC, positive signals of CD146 were detectable in the presence of HUVECs, whereas
connexin 43 protein levels were only apparent in a mono- or coculture with MSCs. Scale bars = 100μm.
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Pericytes, which are closely related to MSCs, are involved
in the stabilization of newly formed vessels. Therefore, we
analyzed the expression of CD146, NG-2, and PDGFRβ1 as
putative pericyte markers (Figures 6(d)–6(f)). For CD146,
gene expression of MSC monocultures revealed a slight
upregulation on day 7 (p > 0 05, Figure 6(d)). In contrast,
NG-2 gene expression, which was completely absent in
HUVEC monocultures, was downregulated in the MSC
monoculture and tended to be stable in cocultures (fold
change: 100M 0.1 versus 75HM 0.9±0.3 and 50HM 0.6
±0.2, all p > 0 05). Besides the lack of NG-2 expression in
HUVEC monocultures, no diﬀerences in NG-2 gene regula-
tion were observed at day 14. A trend of upregulation was
apparent for PDGFRβ1 at day 14 with large variations
between diﬀerent cell donors (Figure 6(f)). The highest
upregulation of PDGFRβ1 was detected in HUVEC mono-
cultures (fold change 23.5 ± 17.2, p > 0 05).
Apart from growth factors and their receptors, cell-to-
cell contacts, as well as basal membrane proteins play an
important role in angiogenesis. Connexin 43 is involved
in gap junction cell-to-cell-contacts. A tendency for a
slight upregulation of connexin 43 was observed in MSC
monocultures (Figure 6(g)), whereas no changes were
apparent in collagen IV gene expression, a basal membrane
protein (Figure 6(h)).
3.4. Immunohistological Analysis of CD146 and Connexin 43.
To evaluate speciﬁc markers on protein level, immunohistol-
ogy was performed on cryosections for CD146, a pericyte
marker, and connexin 43, a cell-to-cell contact protein
(Figure 7). CD146 was detectable in the presence of HUVECs
whereas MSCs alone showed similar results than negative
controls indicating that MSC alone did not express CD146
at a detectable level in 3D culture. Connexin 43 was only
present in mono- or cocultures containing MSCs.
4. Discussion
In the context of musculoskeletal regeneration, for example,
bone defects, limitations in the healing process often occur
due to an insuﬃcient blood supply at the defect site. Revascu-
larization involves angiogenic sprouting of vessels from the
surrounding tissue, which frequently does not occur in an
appropriate time, as the ingrowth of vessels is a long-term
process [3]. Therefore, prevascularized implants have been
suggested as a promising treatment strategy [6–15]. The
aim of this study was to create an autologous cell delivery
system for prevascularized constructs within PRP hydrogels.
In the present study, we showed that PRP is indeed a
suitable delivery system for HUVECs, MSCs, and cocultures
of both. Cells survived for a period over 14 days which is in
line with our previous work [33] demonstrating the viability
of MSCs encapsulated in PRP gels for one week.
We noticed that, particularly in the presence of MSCs,
PRP gels shrinked over time. Upon in vivo implantation,
shrinkage of gels and the herewith associated volume loss
may be a limitation for the use of PRP as a cell delivery
system. However, shrinkage of gels was not directly related
to the formation of networks. In fact, cell assembly to
tube-like structures occurred as early as 3 days in cell culture,
and thereby, this preceded the signiﬁcant reduction of gel
volume observed after 7 days. This indicates that early
implantation of prevascularized PRP gels would be desirable.
Short in vitro culture periods would also be most convenient
for clinical applications. In addition, mesenchyme-driven
condensation of soft matrix has been reported as an impor-
tant step in the formation of organ buds and the regeneration
of functional vascularized tissues [47]. Therefore, the
observed shrinkage, which in line with ﬁndings from Takebe
et al. was mainly driven by MSCs, may be considered as
natural step in matrix remodeling.
We observed that PRP gels with cocultures of HUVECs
and MSCs formed networks as early as 3 days after cell
encapsulation, which were still stable after 2 weeks. This fast
network formation might be stimulated by the growth factors
secreted from PRP gels [33]. Indeed, since cells were resus-
pended in PRP upon activation with thrombin, they were
immediately exposed to the growth factor release.
In agreement with earlier studies [10, 11, 48], cells
(HUVECs and MSCs) took advantage of coculturing. In
contrast, no stable networks could be detected in HUVEC
monocultures. The maturation of new blood vessels
requires the recruitment of mural cells (pericytes or smooth
muscle cells) [49] to be stable in the long term. Pericytes
are found as single cells, distributed at discontinuous inter-
vals along the basal membrane, which they share with
endothelial cells [50]. During angiogenesis, pericytes are
stimulated for migration and proliferation before they are
recruited to new vessels to contribute to stability. Recently,
we have investigated the plasticity of MSCs and their ability
to diﬀerentiate into a pericyte-like phenotype [51]. This
study showed that MSCs upregulated the expression of
pericyte markers such as NG-2 and CD146 when they are
in direct coculture with bone marrow-derived EPCs [51].
Similarly, Goerke and colleagues showed diﬀerentiation of
MSCs towards a smooth muscle cell phenotype when
coincubated with blood derived EPCs [52]. In line with
these ﬁndings, MSC supplementation has been proven to
promote the formation of stable vessels in various in vitro
and in vivo studies [9, 10, 13, 15, 23, 53]. For example,
our previous work showed that tissue-engineered constructs
composed of EPC-MSC cocultures delivered in PU scaﬀold
in the presence of PRP, promoted vascularization upon
subcutaneous implantation [15]. Furthermore, we observed
that MSCs indeed display a pericyte-like phenotype in these
cocultures [23].
Pericytes, best deﬁned based on their in vivo localization,
express several surface markers including CD146 [54, 55],
NG-2 [56], α-SMA [57], and PDGFRβ1 [58], which is how-
ever dependent on their localization [59]. In the present
study, we analyzed the gene expression of CD146, NG-2,
and PDGFRβ1. Results gave evidence for a diﬀerentiation
of MSCs into a pericyte-like phenotype as described above.
This was particularly obvious by a much higher expression
of NG-2 in cocultures in comparison to HUVEC monocul-
tures. Moreover, we detected a general upregulation of
PDGFRβ1 in all cultures. The PDGFβ/PDGFRβ pathway is
critically important for the expansion of the pericyte
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population and pericyte migration along growing vessels
[60]. Therefore, upregulation of its gene expression in cocul-
tures might reﬂect the diﬀerentiation and recruitment of
MSCs towards the vessel-like structures in PRP gels. Strik-
ingly, also HUVEC monocultures showed an upregulation
of PDGFRβ gene expression. Although, endothelial cells
usually do not express PDGFRβ1 in high quantities and the
relevance of this receptor is unclear in resting endothelium,
the current literature provides evidence that PDGFRβ is
upregulated under circumstances of angiogenesis [61–63].
Therefore, we hypothesize that PDGFRβ upregulation in
HUVEC cultures might be caused by the formation of tube-
like networks and possibly might be a response to the absence
of supporting mural cells. Taken together, in the current
study, we only detected a relatively mild increase in the
expression of pericyte marker missing statistical signiﬁcance.
Since changes in gene expression are generally transient, it is
likely that we might have missed certain changes because
only two time points were assessed.
Various signaling pathways are involved in angiogenesis,
and it would be of most interest to perform a broad screening
of factors involved in the proangiogenic functions of PRP. In
this ﬁrst evaluation of PRP gel as a proangiogenic cell
delivery system, we however focused on few key players in
angiogenesis; future studies will thoroughly investigate the
mechanism of tube-like structure formation in PRP gels.
One major growth factor is angiopoietin 1 which acts as a
survival signal for endothelial cells and further promotes
vascular stabilization by facilitating pericyte recruitment
[64, 65]. Here, we show a tendency of angiopoietin 1 upreg-
ulation, with the highest upregulations in cocultures of
HUVECs and MSCs on day 7 and day 14. However, Tie 2,
which is constitutively activated by basal angiopoietin 1
expression [66], was not expressed. An explanation might
be the general high expression of Tie 2 on surfaces of mature
endothelial cells (HUVECs) which could be seen in gene
expression in monoculture conditions. In addition, Tie 2
expression may be delayed to angiopoietin 1 and therefore
not be seen at the analysis time points.
In respect of angiogenesis, VEGF is another crucial
growth factor for inducing new vessel formation. The fact
that the applied growth medium EGM-2 as well as PRP itself
already contains VEGF might be a reason why we could not
ﬁnd an upregulation of VEGF gene expression. Moreover,
previous studies reported comparable ﬁndings since it was
shown that new vessel formation is not generally associated
with changes in VEGF expression [67, 68].
Moreover, we investigated the expression of the speciﬁc
cell-to-cell contact protein connexin 43 and found that it
was expressed in dependence of MSCs, especially on day
14. Connexin 43 is part of gap junctions and expressed on
endothelial cells [69]. In addition, it was previously shown
that MSCs overexpressing connexin 43 promote neovascu-
larization [70]. Furthermore, Wang et al. proposed that
connexin 43 may act as a potential target for improving the
therapeutic eﬃcacy of MSC transplantation. In line with that,
we found MSC-dependent expression of connexin 43 on
both gene and protein levels. Since vascular network struc-
tures were only stable in dependence of MSCs, this leads to
the hypothesis that connexin 43 expressed on MSCs may
contribute to stabilization processes of cellular networks.
In this study, we present for the ﬁrst time an autologous
delivery system for prevascularized constructs. PRP can eas-
ily be harvested by drawing blood which may facilitate the
next steps to clinical applications. The fact that PRP is more
and more used in clinical studies [29, 32, 71] emphasizes its
importance in musculoskeletal healing processes. We dem-
onstrate that PRP has a great potential to support neovascu-
larization, which is a major clinical challenge, particularly in
the context of bone repair. While the study conﬁrmed PRP as
autologous and proangiogenic cell delivery system, the endo-
thelial cell source (HUVECs) used here cannot be obtained
autologously. However, at this stage, we focused on the inves-
tigation of these proangiongenic properties of PRP; future
studies will address the use of autologous cell sources such
as peripheral blood or bone marrow-derived EPCs.
Since the current study is an in vitro experiment, it can-
not foresee how cellular networks will sustain in an in vivo
environment and how cell-to-cell communication and a
supposedly fast in vivo degradation of PRP will impact the
stability of tubular structures as well as the anastomosis to
the host vascular system. In addition, future studies should
be conducted to optimize the system for the application
in vivo. These studies should address the implantation
technique and time point as well as cell seeding densities.
Eventually, it will be interesting to test whether a delivery
of cells is necessary or if the chemoattractive and proangio-
genic properties of PRP themselves may be suﬃcient to
support neovascularization.
5. Conclusion
To our knowledge, this is the ﬁrst study to report on an autol-
ogous cell delivery system for the delivery of prevascularized
structures. Our study shows stable formation of cellular
networks by combining HUVECs and MSCs in one culture
system. The contribution of MSCs, possibly diﬀerentiating
into a pericyte-like phenotype, may be crucial for the
stabilization of cellular networks.
In conclusion, we demonstrate that PRP can be used as
an autologous, proangiogenic cell delivery system promoting
early neovascularization.
Disclosure
Marietta Herrmann’s current address is IZKF Group Tissue
Regeneration in Musculoskeletal Diseases, Orthopedic Center
for Musculoskeletal Research, University Würzburg, Germany.
Conflicts of Interest
The authors declare no conﬂicts of interests.
Acknowledgments
The authors wish to thank Andri Hassler and Maria
Hildebrand for their technical assistance. This work was
funded by the AO Foundation, and a PROMOS Fellowship
11Mediators of Inﬂammation
of University Regensburg was awarded to Jessica Zahn. This
workwas also supported by theGermanResearch Foundation
(DFG) within the funding program Open Access Publishing.
References
[1] R. A. D. Carano and E. H. Filvaroﬀ, “Angiogenesis and bone
repair,” Drug Discovery Today, vol. 8, pp. 980–989, 2003.
[2] E. O. Johnson, T. Troupis, and P. N. Soucacos, “Tissue-
engineered vascularized bone grafts: basic science and clini-
cal relevance to trauma and reconstructive microsurgery,”
Microsurgery, vol. 31, pp. 176–182, 2011.
[3] M. W. Laschke and M. D. Menger, “Vascularization in tissue
engineering: angiogenesis versus inosculation,” European
Surgical Research, vol. 48, pp. 85–92, 2012.
[4] F. A. Auger, L. Gibot, and D. Lacroix, “The pivotal role of
vascularization in tissue engineering,” in Annual Review of
Biomedical Engineering, M. L. Yarmush, Ed., vol. 15,
pp. 177–200, Annual Reviews, Palo Alto, 2013.
[5] M. W. Laschke, Y. Harder, M. Amon et al., “Angiogenesis in
tissue engineering: breathing life into constructed tissue
substitutes,” Tissue Engineering, vol. 12, pp. 2093–2104, 2006.
[6] P. L. Tremblay, V. Hudon, F. Berthod, L. Germain, and
F. A. Auger, “Inosculation of tissue-engineered capillaries
with the host’s vasculature in a reconstructed skin trans-
planted on mice,” American Journal of Transplantation,
vol. 5, pp. 1002–1010, 2005.
[7] M. W. Laschke, B. Vollmar, and M. D. Menger, “Inosculation:
connecting the life-sustaining pipelines,” Tissue Engineering
Part B, Reviews, vol. 15, pp. 455–465, 2009.
[8] M. W. Laschke and M. D. Menger, “Prevascularization in
tissue engineering: current concepts and future directions,”
Biotechnology Advances, vol. 34, pp. 112–121, 2016.
[9] J. Rouwkema, J. de Boer, and C. A. Van Blitterswijk, “Endothe-
lial cells assemble into a 3-dimensional prevascular network in
a bone tissue engineering construct,” Tissue Engineering,
vol. 12, pp. 2685–2693, 2006.
[10] O. Tsigkou, I. Pomerantseva, J. A. Spencer et al., “Engineered
vascularized bone grafts,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 107,
pp. 3311–3316, 2010.
[11] L. L. Ren, D. Y. Ma, B. Liu et al., “Preparation of three-
dimensional vascularized MSC cell sheet constructs for tissue
regeneration,” BioMed Research International, vol. 2014,
Article ID 301279, 10 pages, 2014.
[12] F. E. Freeman, A. B. Allen, H. Y. Stevens, R. E. Guldberg,
and L. M. McNamara, “Eﬀects of in vitro endochondral prim-
ing and pre-vascularisation of human MSC cellular aggregates
in vivo,” Stem Cell Research & Therapy, vol. 6, p. 218, 2015.
[13] X. Chen, A. S. Aledia, S. A. Popson, L. Him, C. C. Hughes, and
S. C. George, “Rapid anastomosis of endothelial progenitor
cell-derived vessels with host vasculature is promoted by a
high density of cotransplanted ﬁbroblasts,” Tissue Engineering
Part A, vol. 16, pp. 585–594, 2010.
[14] H. Pang, X. H. Wu, S. L. Fu et al., “Prevascularisation with
endothelial progenitor cells improved restoration of the
architectural and functional properties of newly formed bone
for bone reconstruction,” International Orthopaedics, vol. 37,
pp. 753–759, 2013.
[15] M. Herrmann, A. Binder, U. Menzel, S. Zeiter, M. Alini, and S.
Verrier, “CD34/CD133 enriched bonemarrow progenitor cells
promote neovascularization of tissue engineered constructs
in vivo,” Stem Cell Research, vol. 13, pp. 465–477, 2014.
[16] F. S. Frueh, T. Spater, N. Lindenblatt et al., “Adipose tissue-
derived microvascular fragments improve vascularization,
lymphangiogenesis, and integration of dermal skin substi-
tutes,” The Journal of Investigative Dermatology, vol. 137,
pp. 217–227, 2017.
[17] E. Groppa, S. Brkic, E. Bovo et al., “VEGF dose regulates
vascular stabilization through semaphorin3A and the neuropi-
lin-1(+) monocyte/TGF-1 paracrine axis,” EMBO Molecular
Medicine, vol. 7, pp. 1366–1384, 2015.
[18] L. Senzel, D. V. Gnatenko, and W. F. Bahou, “The platelet
proteome,” Current Opinion in Hematology, vol. 16,
pp. 329–333, 2009.
[19] R. P. Zahedi, U. Lewandrowski, J. Wiesner et al., “Phosphopro-
teome of resting human platelets,” Journal of Proteome
Research, vol. 7, pp. 526–534, 2008.
[20] M. Ferrari, S. Zia, M. Valbonesi et al., “A new technique
for hemodilution, preparation of autologous platelet-rich
plasma and intraoperative blood salvage in cardiac-surgery,”
The International Journal of Artiﬁcial Organs, vol. 10,
pp. 47–50, 1987.
[21] R. M. Thushara, M. Hemshekhar, Basappa, K. Kemparaju,
K. S. Rangappa, and K. S. Girish, “Biologicals, platelet
apoptosis and human diseases: an outlook,” Critical Reviews
in Oncology/Hematology, vol. 93, pp. 149–158, 2015.
[22] S. Lippross, M. Loibl, S. Hoppe et al., “Platelet released growth
factors boost expansion of bone marrow derived CD34(+)
and CD133(+) endothelial progenitor cells for autologous
grafting,” Platelets, vol. 22, pp. 422–432, 2011.
[23] F. Duttenhoefer, R. Lara de Freitas, T. Meury et al., “3D
scaﬀolds co-seeded with human endothelial progenitor and
mesenchymal stem cells: evidence of prevascularisation within
7 days,” European Cells & Materials, vol. 26, pp. 49–64, 2013,
discussion -5.
[24] R. E. Marx, “Platelet-rich plasma (PRP): what is PRP and what
is not PRP?,” Implant Dentistry, vol. 10, pp. 225–228, 2001.
[25] C. Cavallo, G. Filardo, E. Mariani et al., “Comparison of
platelet-rich plasma formulations for cartilage healing: an
in vitro study,”The Journal of Bone and Joint SurgeryAmerican,
vol. 96, pp. 423–429, 2014.
[26] X. Xie, C. Zhang, and R. S. Tuan, “Biology of platelet-rich
plasma and its clinical application in cartilage repair,” Arthritis
Research & Therapy, vol. 16, p. 204, 2014.
[27] L. Andriolo, B. Di Matteo, E. Kon, G. Filardo, G. Venieri, and
M. Marcacci, “PRP augmentation for ACL reconstruction,”
BioMed Research International, vol. 2015, Article ID 371746,
15 pages, 2015.
[28] H. J. Braun, A. S. Wasterlain, and J. L. Dragoo, “The use of PRP
in ligament and meniscal healing,” Sports Medicine and
Arthroscopy Review, vol. 21, pp. 206–212, 2013.
[29] B. Di Matteo, M. Loibl, L. Andriolo et al., “Biologic agents for
anterior cruciate ligament healing: a systematic review,”World
Journal of Orthopedics, vol. 7, pp. 592–603, 2016.
[30] J. F. Kaux, P. V. Drion, A. Colige et al., “Eﬀects of platelet-rich
plasma (PRP) on the healing of Achilles tendons of rats,”
Wound Repair and Regeneration, vol. 20, pp. 748–756, 2012.
[31] G. Filardo, E. Kon, B. Di Matteo et al., “Platelet-rich
plasma injections for the treatment of refractory Achilles
tendinopathy: results at 4 years,” Blood Transfusion, vol. 12,
pp. 533–540, 2014.
12 Mediators of Inﬂammation
[32] A. Rowden, P. Dominici, J. D'Orazio et al., “Double-blind,
randomized, placebo-controlled study evaluating the use of
platelet-rich plasma therapy (PRP) for acute ankle sprains
in the emergency department,” The Journal of Emergency
Medicine, vol. 49, pp. 546–551, 2015.
[33] J. M. Jalowiec, M. D'Este, J. J. Bara et al., “An in vitro investiga-
tion of platelet-rich plasma-gel as a cell and growth factor
delivery vehicle for tissue engineering,” Tissue Engineering
Part C, Methods, vol. 22, pp. 49–58, 2016.
[34] M. Loibl, S. Lang, G. Brockhoﬀ et al., “The eﬀect of
leukocyte-reduced platelet-rich plasma on the proliferation
of autologous adipose-tissue derived mesenchymal stem
cells,” Clinical Hemorheology and Microcirculation, vol. 61,
pp. 599–614, 2016.
[35] M. Loibl, S. Lang, A. Hanke et al., “Leukocyte-reduced platelet-
rich plasma alters protein expression of adipose tissue-derived
mesenchymal stem cells,” Plastic and Reconstructive Surgery,
vol. 138, pp. 397–208, 2016.
[36] C. E. Martinez, S. A. Gonzalez, V. Palma, and P. C. Smith,
“Platelet-poor and platelet-rich plasma stimulate bone lineage
diﬀerentiation in periodontal ligament stem cells,” Journal of
Periodontology, vol. 87, pp. E18–E26, 2016.
[37] G. Gobbi and M. Vitale, “Platelet-rich plasma preparations
for biological therapy: applications and limits,” Operative
Techniques in Orthopaedics, vol. 22, pp. 10–15, 2012.
[38] D. M. Dohan Ehrenfest, I. Andia, M. A. Zumstein, C.-Q.
Zhang, N. R. Pinto, and T. Bielecki, “Classiﬁcation of platelet
concentrates (platelet-rich plasma-PRP, platelet-rich ﬁbrin-
PRF) for topical and inﬁltrative use in orthopedic and sports
medicine: current consensus, clinical implications and per-
spectives,” Muscles, Ligaments and Tendons Journal, vol. 4,
pp. 3–9, 2014.
[39] K. Mautner, G. A. Malanga, J. Smith et al., “A call for a
standard classiﬁcation system for future biologic research:
the rationale for new PRP nomenclature,” PM & R, vol. 7,
pp. S53–S59, 2015.
[40] A. Lubkowska, B. Dolegowska, and G. Banﬁ, “Growth factor
content in PRP and their applicability in medicine,” Journal
of Biological Regulators and Homeostatic Agents, vol. 26,
pp. 3S–22S, 2012.
[41] S. G. Boswell, L. V. Schnabel, H. O. Mohammed, E. A.
Sundman, T. Minas, and L. A. Fortier, “Increasing platelet
concentrations in leukocyte-reduced platelet-rich plasma
decrease collagen gene synthesis in tendons,” The American
Journal of Sports Medicine, vol. 42, pp. 42–49, 2014.
[42] A. D. Mazzocca, M. B. R. McCarthy, D. M. Chowaniec et al.,
“The positive eﬀects of diﬀerent platelet-rich plasma methods
on human muscle, bone, and tendon cells,” The American
Journal of Sports Medicine, vol. 40, pp. 1742–1749, 2012.
[43] E. A. Sundman, B. J. Cole, V. Karas et al., “The anti-
inﬂammatory and matrix restorative mechanisms of platelet-
rich plasma in osteoarthritis,” The American Journal of Sports
Medicine, vol. 42, pp. 35–41, 2014.
[44] J. Kurita, M. Miyamoto, Y. Ishii et al., “Enhanced vasculariza-
tion by controlled release of platelet-rich plasma impregnated
in biodegradable gelatin hydrogel,” The Annals of Thoracic
Surgery, vol. 92, pp. 837–844, 2011, discussion 44.
[45] J. Zahn, M. Herrmann, M. Loibl, M. Alini, and S. Verrier,
“Platelet-rich plasma as autologous cell delivery and pro-
angiogenic hydrogel for bone tissue engineering,” Bone & Joint
Journal, vol. 99-B, Supplement 2, p. 87, 2017.
[46] M. Herrmann, J. J. Bara, C. M. Sprecher et al., “Pericyte
plasticity - comparative investigation of the angiogenic
and multilineage potential of pericytes from diﬀerent
human tissues,” European Cells & Materials, vol. 31,
pp. 236–249, 2016.
[47] T. Takebe, M. Enomura, E. Yoshizawa et al., “Vascularized and
complex organ buds from diverse tissues via mesenchymal cell-
driven condensation,” Cell Stem Cell, vol. 16, pp. 556–565, 2015.
[48] J. L. Ma, F. Yang, S. K. Both et al., “In vitro and in vivo
angiogenic capacity of BM-MSCs/HUVECs and AT-MSCs/
HUVECs cocultures,” Biofabrication, vol. 6, p. 10, 2014.
[49] S. Reginato, R. Gianni-Barrera, and A. Banﬁ, “Taming of the
wild vessel: promoting vessel stabilization for safe therapeutic
angiogenesis,” Biochemical Society Transactions, vol. 39,
pp. 1654–1658, 2011.
[50] A. Armulik, G. Genove, and C. Betsholtz, “Pericytes:
developmental, physiological, and pathological perspectives,
problems, and promises,” Developmental Cell, vol. 21,
pp. 193–215, 2011.
[51] M. Loibl, A. Binder, M. Herrmann et al., “Direct cell-cell
contact between mesenchymal stem cells and endothelial
progenitor cells induces a pericyte-like phenotype in vitro,”
BioMed Research International, vol. 2014, Article ID 395781,
10 pages, 2014.
[52] S. M. Goerke, J. Plaha, S. Hager et al., “Human endothelial
progenitor cells induce extracellular signal-regulated kinase-
dependent diﬀerentiation of mesenchymal stem cells into
smooth muscle cells upon cocultivation,” Tissue Engineering
Part A, vol. 18, pp. 2395–2405, 2012.
[53] P. Au, J. Tam, D. Fukumura, and R. K. Jain, “Bone
marrow-derived mesenchymal stem cells facilitate engineer-
ing of long-lasting functional vasculature,” Blood, vol. 111,
pp. 4551–4558, 2008.
[54] Q. Li, Y. Yu, J. Bischoﬀ, J. B. Mulliken, and B. R. Olsen, “Diﬀer-
ential expression of CD146 in tissues and endothelial cells
derived from infantile haemangioma and normal human
skin,” The Journal of Pathology, vol. 201, pp. 296–302, 2003.
[55] D. T. Covas, R. A. Panepucci, A. M. Fontes et al., “Multipotent
mesenchymal stromal cells obtained from diverse human
tissues share functional properties and gene-expression proﬁle
with CD146(+) perivascular cells and ﬁbroblasts,” Experimen-
tal Hematology, vol. 36, pp. 642–654, 2008.
[56] F. J. Huang, W. K. You, P. Bonaldo, T. N. Seyfried, E. B.
Pasquale, and W. B. Stallcup, “Pericyte deﬁciencies lead to
aberrant tumor vascularizaton in the brain of the NG2 null
mouse,” Developmental Biology, vol. 344, pp. 1035–1046,
2010.
[57] V. Nehls and D. Drenckhahn, “The versatility of microvascular
pericytes - from mesenchyme to smooth-muscle,” Histochem-
istry, vol. 99, pp. 1–12, 1993.
[58] E. A. Winkler, R. D. Bell, and B. V. Zlokovic, “Pericyte-speciﬁc
expression of PDGF beta receptor in mouse models with nor-
mal and deﬁcient PDGF beta receptor signaling,” Molecular
Neurodegeneration, vol. 5, p. 11, 2010.
[59] L. Diaz-Flores, R. Gutierrez, J. F. Madrid et al., “Pericytes.
Morphofunction, interactions and pathology in a quiescent
and activated mesenchymal cell niche,” Histology and
Histopathology, vol. 24, pp. 909–969, 2009.
[60] A. Armulik, A. Abramsson, and C. Betsholtz, “Endothelial/
pericyte interactions,” Circulation Research, vol. 97, pp. 512–
523, 2005.
13Mediators of Inﬂammation
[61] M. Hermansson, M. Nister, C. Betsholtz, C. H. Heldin, B.
Westermark, and K. Funa, “Endothelial-cell hyperplasia in
human glioblastoma - coexpression of messenger RNA for
platelet-derived growth-factor (PDGF) b-cain and PDGF
receptor suggests autocrine growth-stimulation,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 85, pp. 7748–7752, 1988.
[62] K. H. Plate, G. Breier, C. L. Farrell, and W. Risau, “Platelet-
derived growth factor receptor-beta is induced during tumor-
development and up-regulated during tumor progression in
endothelial-cells in human gliomas,” Laboratory Investigation,
vol. 67, pp. 529–534, 1992.
[63] M. W. von Ballmoos, Z. J. Yang, J. Volzmann, I. Baumgartner,
C. Kalka, and S. Di Santo, “Endothelial progenitor cells induce
a phenotype shift in diﬀerentiated endothelial cells towards
PDGF/PDGFR beta axis-mediated angiogenesis,” PLoS One,
vol. 5, p. 10, 2010.
[64] T. Hawighorst, M. Skobe, M. Streit et al., “Activation of the
Tie2 receptor by angiopoietin-1 enhances tumor vessel matu-
ration and impairs squamous cell carcinoma growth,” The
American Journal of Pathology, vol. 160, pp. 1381–1392, 2002.
[65] E. Fagiani and G. Christofori, “Angiopoietins in angiogenesis,”
Cancer Letters, vol. 328, pp. 18–26, 2013.
[66] P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a
natural antagonist for Tie2 that disrupts in vivo angiogenesis,”
Science, vol. 277, pp. 55–60, 1997.
[67] L. E. Benjamin, I. Hemo, and E. Keshet, “A plasticity
window for blood vessel remodelling is deﬁned by peri-
cyte coverage of the preformed endothelial network and is
regulated by PDGF-B and VEGF,” Development, vol. 125,
pp. 1591–1598, 1998.
[68] L. E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet,
“Selective ablation of immature blood vessels in established
human tumors follows vascular endothelial growth factor
withdrawal,” The Journal of Clinical Investigation, vol. 103,
pp. 159–165, 1999.
[69] F. Villars, B. Guillotin, T. Amedee et al., “Eﬀect of HUVEC on
human osteoprogenitor cell diﬀerentiation needs heterotypic
gap junction communication,” American Journal of Physiology
Cell Physiology, vol. 282, pp. C775–C785, 2002.
[70] D. G. Wang, F. X. Zhang, M. L. Chen, H. J. Zhu, B. Yang, and
K. J. Cao, “Cx43 in mesenchymal stem cells promotes angio-
genesis of the infarcted heart independent of gap junctions,”
Molecular Medicine Reports, vol. 9, pp. 1095–1102, 2014.
[71] M. Loibl, S. Lang, L. M. Dendl et al., “Leukocyte-reduced
platelet-rich plasma treatment of basal thumb arthritis: a
pilot study,” BioMed Research International, vol. 2016,
Article ID 9262909, 6 pages, 2016.
14 Mediators of Inﬂammation
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
